| 2-year overall survival (OS) (%) | p value | 2-year disease-free survival (DSF) (%) | p value |
---|---|---|---|---|
Gender | ||||
 Male | 89.5 | 0.00* | 73.7 | 0.00* |
 Female | 0 | 0 | ||
T stage | ||||
 T2 | 100 | 0.541 | 33.3 | 0.18 |
 T3 | 100 | 50 | ||
 T4 | 75 | 75 | ||
N stage | ||||
 N0 | 100 | 0.738 | 100 | 0.422 |
 N1 | 75 | 50 | ||
 N2 | 81.8 | 72.7 | ||
Skin involvement | ||||
 Present | 100 | 0.242 | 100 | 0.095 |
 Absent | 75 | 56.2 | ||
Bone involvement | ||||
 Present | 90 | 0.282 | 90 | 0.023* |
 Absent | 72.7 | 45.5 | ||
GADD45 | ||||
 0 | 0 | 0.005* | 0 | 0.012* |
 1 | 100 | 100 | ||
 2 | 83.3 | 58.3 | ||
 3 | 100 | 100 | ||
HPV status | ||||
 Positive | 100 | 0.234 | 100 | 0.077** |
 Negative | 75 | 56.2 | ||
EGFR grading | ||||
 1 | 83.3 | 0.566 | 83.3 | 0.518 |
 2 | 60 | 40 | ||
 3 | 90 | 70 | ||
Her-2-neu | ||||
 Positive | 100 | 0.392 | 66.7 | 0.933 |
 Negative | 77.8 | 66.7 | ||
Pathological lymph node involvement | ||||
 Present | 81.8 | 0.899 | 63.7 | 0.47 |
 Absent | 80 | 70 | ||
Vascular invasion | ||||
 Present | 71.4 | 0.273 | 66.7 | 0.86 |
 Absent | 88.9 | 71.4 | ||
Perineural invasion | ||||
 Present | 57.1 | 0.05* | 57.1 | 0.36 |
 Absent | 100 | 77.8 | ||
Lymphatic invasion | ||||
 Present | 71.4 | 0.273 | 66.7 | 0.86 |
 Absent | 88.9 | 71.4 |